AIM
APLS

Assured Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

Assured Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,126
Closed -$119K – 99
2019
Q1 		$119K Buy
6,126
+2,860
+88% +$45K ﹤0.01% 874
2018
Q4 		$43K Buy
+3,266
New +$50.1K ﹤0.01% 1047

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Assured Investment Management's APLS Position: Q2 2019 in Review

Assured Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2019, closing a stake of 6,126 shares — an estimated $119K sold.

Assured Investment Management first reported a position in APLS in Q4 2018 and held it in 2 quarters. The position peaked at $119K in Q1 2019. 99 funds tracked by Wall St. Rank hold APLS as of Q2 2019.

  • Assured Investment Management reported no remaining Apellis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Assured Investment Management sold 6,126 Apellis Pharmaceuticals shares in Q2 2019, an estimated $119K.
  • Assured Investment Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Assured Investment Management's Apellis Pharmaceuticals position peaked at $119K in Q1 2019.
  • 99 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.